Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study.

Cancer·2026
Same author

A comprehensive analysis of Y-chromosomal diversity in Colombian populations.

International journal of legal medicine·2026
Same author

Bacteriocin presence enhances phage-related risks in dairy fermentations.

Food research international (Ottawa, Ont.)·2026
Same author

Immune classification of advanced melanoma identifies non-responders to anti-PD1 therapy.

Cancer immunology, immunotherapy : CII·2026
Same author

The Circadian Oscillator Affects Both Glutathione Homeostasis and Its Response to Salt Stress in Arabidopsis thaliana.

Plant, cell & environment·2026
Same author

Contrasting Maternal, Paternal, and Biparental Ancestry of Populations From the Caribbean Coast of Colombia.

American journal of biological anthropology·2026

Related Experiment Videos

Symptom clusters in advanced cancer.

Ana Jiménez1, Rosario Madero, Alberto Alonso

  • 1Getafe University Hospital, Getafe, Spain. jaimefeliu@hotmail.com

Journal of Pain and Symptom Management
|March 16, 2011
PubMed
Summary
This summary is machine-generated.

Symptom clusters in advanced cancer patients are linked to cancer type, demographics, and performance status. Identifying these symptom clusters can help predict patient survival outcomes.

Related Experiment Videos

Area of Science:

  • Palliative Care
  • Oncology
  • Symptom Science

Background:

  • Advanced cancer patients frequently experience multiple symptoms concurrently.
  • Limited research exists on symptom clusters (SCs) within this patient population.

Purpose of the Study:

  • To explore symptom clusters (SCs) in advanced cancer patients.
  • To evaluate characteristics associated with identified SCs.
  • To determine the relationship between SCs and patient survival.

Main Methods:

  • Utilized data from 406 patients in a palliative care program (2003-2005).
  • Employed the Edmonton Symptom Assessment System and a supplementary symptom checklist.
  • Conducted principal component analysis to identify symptom relationships and compare SCs with patient parameters.

Main Results:

  • Identified four distinct SCs: confusion, neuropsychological, anorexia-cachexia, and gastrointestinal.
  • Found that SCs were influenced by primary cancer site, gender, age, and performance status.
  • Demonstrated a significant relationship between the number of SCs and survival duration (P < 0.001).

Conclusions:

  • Distinct symptom clusters (SCs) are identifiable in advanced cancer patients.
  • SCs are influenced by clinical and demographic factors, including primary cancer site, gender, age, and performance status.
  • The identified SCs possess prognostic value for patient survival.